Selective Priming of Tumor Blood Vessels by Radiation Therapy Enhances Nanodrug Delivery.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
01 11 2019
Historique:
received: 18 06 2019
accepted: 11 09 2019
entrez: 3 11 2019
pubmed: 5 11 2019
medline: 28 10 2020
Statut: epublish

Résumé

Effective drug delivery is restricted by pathophysiological barriers in solid tumors. In human pancreatic adenocarcinoma, poorly-permeable blood vessels limit the intratumoral permeation and penetration of chemo or nanotherapeutic drugs. New and clinically viable strategies are urgently sought to breach the neoplastic barriers that prevent effective drug delivery. Here, we present an original idea to boost drug delivery by selectively knocking down the tumor vascular barrier in a human pancreatic cancer model. Clinical radiation activates the tumor endothelial-targeted gold nanoparticles to induce a physical vascular damage due to the high photoelectric interactions. Active modulation of these tumor neovessels lead to distinct changes in tumor vascular permeability. Noninvasive MRI and fluorescence studies, using a short-circulating nanocarrier with MR-sensitive gadolinium and a long-circulating nanocarrier with fluorescence-sensitive nearinfrared dye, demonstrate more than two-fold increase in nanodrug delivery, post tumor vascular modulation. Functional changes in altered tumor blood vessels and its downstream parameters, particularly, changes in K

Identifiants

pubmed: 31676822
doi: 10.1038/s41598-019-50538-w
pii: 10.1038/s41598-019-50538-w
pmc: PMC6825216
doi:

Substances chimiques

Gold 7440-57-5

Types de publication

Journal Article Research Support, Non-U.S. Gov't Retracted Publication

Langues

eng

Sous-ensembles de citation

IM

Pagination

15844

Subventions

Organisme : NCI NIH HHS
ID : R21 CA188833
Pays : United States

Commentaires et corrections

Type : ErratumIn
Type : RetractionIn

Références

Sci Am. 1994 Jul;271(1):58-65
pubmed: 8066425
Nano Lett. 2014 Feb 12;14(2):972-81
pubmed: 24422585
Phys Med Biol. 2004 Sep 21;49(18):N309-15
pubmed: 15509078
Nano Lett. 2015 Nov 11;15(11):7488-96
pubmed: 26418302
Clin Cancer Res. 2010 Dec 15;16(24):6139-49
pubmed: 20876255
J Control Release. 2000 Feb 14;64(1-3):63-79
pubmed: 10640646
Nat Nanotechnol. 2011 Oct 23;6(12):815-23
pubmed: 22020122
Adv Drug Deliv Rev. 2010 Feb 17;62(2):167-83
pubmed: 19951733
Mol Cancer Ther. 2016 May;15(5):998-1007
pubmed: 26939698
Semin Radiat Oncol. 2016 Oct;26(4):320-37
pubmed: 27619253
CA Cancer J Clin. 2017 Jan;67(1):7-30
pubmed: 28055103
Transl Cancer Res. 2013 Aug;2(4):
pubmed: 24392307
Cancer Res. 2013 Apr 15;73(8):2412-7
pubmed: 23423979
Nat Rev Clin Oncol. 2016 Dec;13(12):750-765
pubmed: 27531700
J Control Release. 2016 Dec 28;244(Pt B):247-256
pubmed: 27590214
Nat Biotechnol. 2015 Sep;33(9):941-51
pubmed: 26348965
Nanomedicine (Lond). 2016 Sep;11(18):2405-17
pubmed: 27529506
Biomed Res Int. 2014;2014:418624
pubmed: 24987682
Science. 2003 May 16;300(5622):1155-9
pubmed: 12750523
Clin Cancer Res. 2002 May;8(5):1038-44
pubmed: 12006516
ACS Nano. 2013 Jan 22;7(1):252-62
pubmed: 23067565
Int J Radiat Oncol Biol Phys. 2011 Sep 1;81(1):270-6
pubmed: 21163591
Int J Radiat Oncol Biol Phys. 2016 Mar 15;94(4):755-65
pubmed: 26972648
Science. 1998 Jan 16;279(5349):377-80
pubmed: 9430587
Eur J Pharm Biopharm. 2011 Apr;77(3):407-16
pubmed: 21195759
Proc Natl Acad Sci U S A. 2015 Apr 28;112(17):5372-6
pubmed: 25870296
J Control Release. 2013 Dec 10;172(2):504-12
pubmed: 23697767
Eur J Pharm Sci. 2010 Nov 20;41(3-4):473-82
pubmed: 20696244
Chemistry. 2013 May 3;19(19):6122-36
pubmed: 23512788
ACS Nano. 2017 Aug 22;11(8):7807-7820
pubmed: 28640995
Nano Lett. 2011 Oct 12;11(10):4029-36
pubmed: 21846107
Angew Chem Int Ed Engl. 2011 Dec 16;50(51):12299-303
pubmed: 22057640
Chem Soc Rev. 2006 Mar;35(3):209-17
pubmed: 16505915
J Control Release. 2012 Jun 10;160(2):117-34
pubmed: 22484195
Chem Rev. 2015 Oct 14;115(19):10907-37
pubmed: 26166537
Clin Cancer Res. 2012 Aug 15;18(16):4266-76
pubmed: 22896693
Trends Cancer. 2018 Apr;4(4):258-259
pubmed: 29606306
Small. 2005 Mar;1(3):325-7
pubmed: 17193451
Nanomedicine (Lond). 2013 Oct;8(10):1601-9
pubmed: 23265347
Ann Oncol. 2004 Mar;15(3):440-9
pubmed: 14998846
ACS Nano. 2015 Aug 25;9(8):7925-39
pubmed: 26168364
J Pharm Pharmacol. 2008 Aug;60(8):977-85
pubmed: 18644191
N Engl J Med. 2014 Nov 27;371(22):2140-1
pubmed: 25427123
J Cell Biol. 2010 Mar 22;188(6):759-68
pubmed: 20231381
Sci Transl Med. 2011 Apr 20;3(79):79ra33
pubmed: 21508310
Cell Tissue Res. 2009 Jan;335(1):241-8
pubmed: 18752004
J Control Release. 2016 Sep 28;238:103-113
pubmed: 27423325
J Control Release. 2016 Jun 10;231:77-85
pubmed: 26878973
N Engl J Med. 2013 Oct 31;369(18):1691-703
pubmed: 24131140

Auteurs

Sijumon Kunjachan (S)

Department of Radiation Oncology, Brigham and Women's Hospital, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, United States. sijumon@gmail.com.

Shady Kotb (S)

Department of Radiation Oncology, Brigham and Women's Hospital, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, United States.
Institut Lumière Matière, UMR 5306, Université Claude Bernard Lyon 1, CNRS, Villeurbanne, France.

Robert Pola (R)

Institute of Macromolecular Chemistry, Academy of Sciences of the Czech Republic, Heyrovsky Square 2, 16206, Prague 6, Czech Republic.

Michal Pechar (M)

Institute of Macromolecular Chemistry, Academy of Sciences of the Czech Republic, Heyrovsky Square 2, 16206, Prague 6, Czech Republic.

Rajiv Kumar (R)

Department of Radiation Oncology, Brigham and Women's Hospital, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, United States.
Nanomedicine Science and Technology Center and Department of Physics, Northeastern University, Boston, MA, United States.

Bijay Singh (B)

Nanomedicine Science and Technology Center and Department of Physics, Northeastern University, Boston, MA, United States.

Felix Gremse (F)

Experimental Molecular Imaging, University Hospital and Helmholtz Institute for Biomedical Engineering, RWTH Aachen University, Aachen, Germany.

Reza Taleeli (R)

Division of Medical Physics & Engineering, University of Texas Southwestern Medical Center, Texas, United States.

Florian Trichard (F)

Institut Lumière Matière, UMR 5306, Université Claude Bernard Lyon 1, CNRS, Villeurbanne, France.

Vincent Motto-Ros (V)

Institut Lumière Matière, UMR 5306, Université Claude Bernard Lyon 1, CNRS, Villeurbanne, France.

Lucie Sancey (L)

Institute for Advanced Biosciences, UGA/INSERM U1209/CNRS UMR 5309 Joint Research Center, Grenoble, France.

Alexandre Detappe (A)

Department of Radiation Oncology, Brigham and Women's Hospital, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, United States.

Sayeda Yasmin-Karim (S)

Department of Radiation Oncology, Brigham and Women's Hospital, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, United States.

Andrea Protti (A)

Lurie Family Imaging Center, Department of Radiology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, United States.

Ilanchezhian Shanmugam (I)

Nanomedicine Science and Technology Center and Department of Physics, Northeastern University, Boston, MA, United States.

Thomas Ireland (T)

LA-ICP-MS and ICP-ES Laboratories, Department of Earth and Environmental Sciences, Boston University, Boston, MA, United States.

Tomas Etrych (T)

Institute of Macromolecular Chemistry, Academy of Sciences of the Czech Republic, Heyrovsky Square 2, 16206, Prague 6, Czech Republic.

Srinivas Sridhar (S)

Department of Radiation Oncology, Brigham and Women's Hospital, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, United States.
Nanomedicine Science and Technology Center and Department of Physics, Northeastern University, Boston, MA, United States.

Olivier Tillement (O)

Institut Lumière Matière, UMR 5306, Université Claude Bernard Lyon 1, CNRS, Villeurbanne, France.

Mike Makrigiorgos (M)

Department of Radiation Oncology, Brigham and Women's Hospital, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, United States.

Ross I Berbeco (RI)

Department of Radiation Oncology, Brigham and Women's Hospital, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, United States.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH